detect coronary artery disease
Heart Test Laboratories will be presenting clinical trial results of their Myovista cardiac screening system at the American Heart Association (AHA) Scientific Sessions in November 2011. The proprietary patent-pending device is a portable diagnostic screening device that uses ECG technology to potentially within minutes. The technology uses three-dimensional mapping and proprietary algorithms that continuously multiplex surface electrodes to provide information in regards to potential obstruction in the coronary arteries. Heart Test Laboratories claim to have an impressive average 90% or greater correlation to an invasive angiogram with the MyoVista technology.